US 12,168,054 B2
Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
Peter Ordentlich, Lexington, MA (US); and Lei Wang, Waltham, MA (US)
Assigned to Syndax Pharmaceuticals, Inc., Waltham, MA (US)
Appl. No. 16/614,863
Filed by SYNDAX PHARMACEUTICALS, INC., Waltham, MA (US)
PCT Filed May 18, 2018, PCT No. PCT/US2018/033324
§ 371(c)(1), (2) Date Nov. 19, 2019,
PCT Pub. No. WO2018/213665, PCT Pub. Date Nov. 22, 2018.
Claims priority of provisional application 62/508,842, filed on May 19, 2017.
Prior Publication US 2020/0171150 A1, Jun. 4, 2020
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 31/4406 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC A61K 39/39541 (2013.01) [A61K 9/0053 (2013.01); A61K 31/4406 (2013.01); A61P 35/00 (2018.01); C07K 16/2866 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 22 Claims
 
1. A method of treating cancer, wherein the method comprises administering to a patient a combination comprising entinostat and an anti-CSF-1R antibody or an antigen-binding fragment thereof, wherein the anti-CSF-1R antibody or the antigen-binding fragment thereof comprises:
(a) a heavy chain, wherein the variable domain of the heavy chain comprises a CDR having the sequence given in SEQ ID NO:4 for CDR-H1, a CDR having the sequence given in SEQ ID NO:5 for CDR-H2 and a CDR having the sequence given in SEQ ID NO:6 for CDR-H3; and
(b) a light chain, wherein the variable domain of the light chain comprises a CDR having the sequence given in SEQ ID NO: 1 for CDR-L1, a CDR having the sequence given in SEQ ID NO:2 for CDR-L2 and a CDR having the sequence given in SEQ ID NO: 3 for CDR-L3.